HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Kura Oncology (NASDAQ:KURA) with a maintained price target of $32.
May 03, 2024 | 7:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kura Oncology receives a reiterated Buy rating from HC Wainwright & Co. with a price target of $32.
The reiteration of a Buy rating by a reputable analyst firm like HC Wainwright & Co. typically signals continued confidence in the company's potential, suggesting a positive outlook for Kura Oncology's stock price in the short term. The maintained price target of $32 indicates the firm's belief in the stock's growth potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100